Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4637445 | 0.65 | — | — | |
| SCHEMBL29801214 | 0.65 | — | — | |
| SCHEMBL27194674 | 0.63 | NOS1 (0.39) | ALDH1A1GAA | |
| SCHEMBL5475039 | 0.63 | NOS1 (0.35) | ALDH1A1GAAKDM4EMAPT | |
| SCHEMBL2896725 | 0.61 | — | — | |
| SCHEMBL22692251 | 0.60 | — | — | |
| SCHEMBL2366282 | 0.60 | — | — | |
| SCHEMBL11525533 | 0.60 | — | — | |
| SCHEMBL21548748 | 0.59 | ALDH1A1 (0.36) | ALDH1A1GAAHPGDHSD17B10KDM4E | |
| SCHEMBL19528693 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3998257-A1 | FLAVAGLINE DERIVATIVES | PIERRE FABRE MEDICAMENT (FR) | 2022-05-18 | — | — | EP | disclosed |
| EP-3418273-B1 | FLAVAGLINE DERIVATIVES | PF MEDICAMENT (FR) | 2022-01-12 | — | — | EP | disclosed |
| US-10519125-B2 | Flavagline derivatives | PIERRE FABRE MEDICAMENT (FR) | 2019-12-31 | — | — | US | disclosed |
| US-20180086729-A1 | FLAVAGLINE DERIVATIVES | PIERRE FABRE MEDICAMENT (FR) | 2018-03-29 | — | — | US | disclosed |
| US-20180086729-A1 | FLAVAGLINE DERIVATIVES | PIERRE FABRE MEDICAMENT (FR) | 2018-03-29 | — | — | US | disclosed |
| US-20170137400-A1 | FLAVAGLINE DERIVATIVES | PIERRE FABRE MEDICAMENT (FR) | 2017-05-18 | — | — | US | disclosed |
| US-20170137400-A1 | FLAVAGLINE DERIVATIVES | PIERRE FABRE MEDICAMENT (FR) | 2017-05-18 | — | — | US | disclosed |
| WO-2016001441-A1 | FLAVAGLINE DERIVATIVES | PIERRE FABRE MEDICAMENT (FR) | 2016-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137400-A1 | FLAVAGLINE DERIVATIVES | GCG, GCGR, KRAS | ALDH1A1 585/4885GAA 25/4885HPGD 72/4885 |
| US-20180086729-A1 | FLAVAGLINE DERIVATIVES | GCG, GCGR, KRAS | ALDH1A1 585/4885GAA 25/4885HPGD 72/4885 |
| US-10519125-B2 | Flavagline derivatives | GCG, GCGR, KRAS | ALDH1A1 585/4885GAA 25/4885HPGD 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.